Formation Bio has raised $372M across 1 funding round. The latest round valued Formation Bio at $1.7B post-money, with a16z on the lead line.
Formation Bio raised $372 million in a Series D round led by a16z at a $1.7 billion valuation, with OpenAI CEO Sam Altman among its investors. The funding is aimed at growing its drug pipeline and expanding its AI-driven development platform.
1 funding round, the latest highlighted.
Formation Bio was founded in 2016, United States.
A primary round — the company sells new shares to investors it selects. $372M raised, led by a16z.
No filing has been made.
1 dated round, newest first.
a16zLEADSSanofiSSequoia
ThriveEEmerson CollectiveSSV Angel GrowthFFPV VenturesLead investors for each round are in the funding timeline.
The closest biotechnology / drug discovery peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Formation Bio is a private company; its shares do not trade on a public exchange.
The last valuation is $1.7B.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
